The TCL1 family of oncoproteins: co-activators of transformation.
about
Mammalian polynucleotide phosphorylase is an intermembrane space RNase that maintains mitochondrial homeostasisExpression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomasTORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformationPathway analysis of primary central nervous system lymphoma.Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo.Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomyMLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signaturesThe TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB.Peptide-mediated activation of Akt and extracellular regulated kinase signaling prevents lymphocyte apoptosis.Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implicationsIdentification of nerve growth factor-responsive element of the TCL1 promoter as a novel negative regulatory element.Functional analysis of Tcl1 using Tcl1-deficient mouse embryonic stem cells.Regulation of cell differentiation by the DNA damage response.TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cellsTcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL)Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.K63-linked ubiquitination in kinase activation and cancer.TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma.Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis from genotoxic stress.Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.Mature T-cell leukemias: Molecular and Clinical Aspects.ZFX regulates glioma cell proliferation and survival in vitro and in vivo.AID-induced genotoxic stress promotes B cell differentiation in the germinal center via ATM and LKB1 signaling.Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children's Oncology Group.Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.TCL1 expression patterns in Waldenström macroglobulinemia.Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages.The cAMP-activated GTP exchange factor, Epac1 upregulates plasma membrane and nuclear Akt kinase activities in 8-CPT-2-O-Me-cAMP-stimulated macrophages: Gene silencing of the cAMP-activated GTP exchange Epac1 prevents 8-CPT-2-O-Me-cAMP activation ofLive-cell molecular analysis of Akt activation reveals roles for activation loop phosphorylation.CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.TCL1 promotes blastomere proliferation through nuclear transfer, but not direct phosphorylation, of AKT/PKB in early mouse embryos.Protein Kinase Targets in Breast Cancer.BRD4 profiling identifies critical Chronic Lymphocytic Leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor.Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
P2860
Q24302448-3730B3F9-BC25-494F-9C0F-2267A7A31CCCQ24657474-A63E60B1-EB6A-441A-9573-39A855CE8E4EQ24674168-8935B6F6-7EA8-41DE-9522-9A97A24617E1Q30481424-363E9B53-47B4-4583-8CB3-4F8D5FC64E7CQ30556645-7123C02C-696E-4AD7-8D06-8682C8293D36Q33417186-FE9B732F-A41D-4146-89BB-09883ABE5AD9Q33473001-5A100B55-32B7-4A92-9959-4F5C0113090BQ33492280-2030C115-CCAB-493D-8514-98E9EC9C35A6Q33789490-B412F7F8-E07F-4648-951E-E9CBC1D670F8Q33816285-877BEB94-D6C1-49A5-B077-815BEDDC729EQ34546650-5F170ADD-CBB7-47E5-8A00-75B1207CDF1FQ34937960-43D40D2B-66FE-4C15-8879-17C936D8D4ADQ34949637-574FFD5B-210F-4B28-8EE1-8B3616A97B0DQ35128888-6B32D3EC-BB03-4FC9-A16A-31D58C971F63Q35784734-16AC439D-5157-4934-95C2-0C992C39C6A4Q35787000-3D34906C-8883-4F06-9B1E-ED450A39A608Q35849088-390FBBE3-DF4C-4BD0-A8C2-26D0E4BE057AQ35971438-F262EE80-5350-452C-AB46-DEE9D6189DE3Q36194235-1E2F3FA3-BD40-4BB8-9302-889D9195BB2FQ37018730-443A9000-2CC4-4FA2-82F6-17D0443F904DQ37246053-716FAB0D-224E-4103-818A-CA23B72E7966Q37362114-90E652B7-1254-452D-B0C3-89F1FC4DDED4Q37374649-9163FEA1-B0A9-4495-B6CE-E76E6639416DQ38175044-805FBAD3-9CDF-4323-B559-01FACA825AD0Q38598546-D6685AC6-0E1F-4DE9-A145-CBCFADBF5FA3Q39209883-CDDF770C-79D2-4521-B587-ED61A42EBD0DQ39652265-7AF4D818-B150-4D00-BB87-01E541F94D09Q40072094-81EE8F15-AA4C-4010-9383-AE956028D52EQ40337152-92895A20-4AB2-4D33-A743-6D258C879397Q41192923-08E2A3F3-B4B5-45FA-A313-D49ADEE33B2DQ41786115-9EF6F3D1-E9C4-48B7-99B8-EEB49F5DCD3CQ42078419-8F4177AB-7B2D-428A-A89C-2866E4421CFEQ42406106-74464DD3-122B-4AA2-835D-098B81E548BEQ42823745-C3D9D658-539B-4E07-97D1-9B71AC8B9652Q43091453-BEAD9CF3-F721-40D8-89DE-F8BE57E06838Q46976988-3369E921-5586-4FC0-AB3E-CC79158620C6Q47351355-7DC659CD-DE85-4C84-958B-6B9EF379F728Q49546562-76824DB5-7F5C-444B-A52C-BEF6679A74F4Q49959048-BD82B51E-CA31-4528-A1F2-2526120CB961Q51007466-3A7D81F7-FFB2-4032-BDB2-C5B58A79AD41
P2860
The TCL1 family of oncoproteins: co-activators of transformation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The TCL1 family of oncoproteins: co-activators of transformation.
@ast
The TCL1 family of oncoproteins: co-activators of transformation.
@en
type
label
The TCL1 family of oncoproteins: co-activators of transformation.
@ast
The TCL1 family of oncoproteins: co-activators of transformation.
@en
prefLabel
The TCL1 family of oncoproteins: co-activators of transformation.
@ast
The TCL1 family of oncoproteins: co-activators of transformation.
@en
P2860
P356
P1476
The TCL1 family of oncoproteins: co-activators of transformation.
@en
P2093
Michael A Teitell
P2860
P2888
P304
P356
10.1038/NRC1672
P407
P577
2005-08-01T00:00:00Z
P5875
P6179
1032506949